On this page

Imizol® Equine Injection

Imidocarb Dipropionate

Veterinary NADA Approved 138 adverse event reports

Overview

Source: Animal Drugs @ FDA
Proprietary name
Imizol® Equine Injection
Active ingredient
Imidocarb Dipropionate
Application type
NADA
Sponsor
Intervet, Inc.
Applications on record
1
First published
June 1, 2016

Adverse event reports

Source: openFDA VeDDRA
138
Reports mentioning this ingredient
June 22, 1998 – October 21, 2021
2
Classified serious
per reporter assessment
11
Lack of expected efficacy
resistance signal
11
Human operator exposure
needle-stick or splash
Not a risk measure. Veterinary adverse event reports are influenced by how many animals are treated, reporting practice and product age. Reports do not establish that the product caused the event, and a single report can cover an entire herd or flock. Attribution here is by active ingredient because the source dataset redacts brand names.

Attributed by active ingredient “IMIDOCARB DIPROPIONATE”. Green Book ingredient names and VeDDRA ingredient names do not always agree exactly, so attribution is approximate and labelled as such.

Reported reactions

Source: openFDA VeDDRA

Clinical signs coded in the VICH VeDDRA four-level hierarchy, most frequent first.

Reaction terms reported for this ingredient, by report count.
Reaction (VeDDRA term) Reports Relative frequency
Death 31
Hypersalivation 25
Vomiting 25
Injection site swelling 21
Diarrhoea 20
Depression 15
Fever 11
Accidental exposure 11
Polypnoea 8
Weakness 8
Unclassifiable adverse event 8
Lack of efficacy (protozoa) - NOS 7
Injection site ulcer 7
Trembling 7
Injection site pain 6
Icterus 6
Dyspnoea 5
Miosis 4
Lack of efficacy - NOS 4
Anaphylaxis 4

Species affected

Source: openFDA VeDDRA
Dog 109 Cattle 9 Cat 7 Human 6 Horse 4 Other Deer 1

Regulatory context

New Animal Drug Application (NADA). A pioneer approval evaluated for target animal safety, therapeutic effectiveness, manufacturing controls and — for food-producing species — human food safety including residue depletion.

Extra-label use in food-producing animals is governed by the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) and 21 CFR Part 530. It requires a valid veterinarian-client-patient relationship and is prohibited outright for certain drug classes. Withdrawal times are determined by FARAD, not by this index.

Sources for this page

Animal Drugs @ FDA FDA CVM Applications, sponsor, status, withdrawal
Animal & Veterinary Events FDA CVM VeDDRA adverse event aggregates by active ingredient